HongDuck Yun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
HongDuck Yun has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Chae-Min Ryu
Center for Cell Therapy, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
2 shared publications - Dong-Myung Shin
Department of Cell and Genetic Engineering, Asan Medical Center, Brain Korea 21 project, University of Ulsan College of Medicine, Seoul, Republic of Korea
2 shared publications - Hwan Yeul Yu
UroGyn Efficacy Evaluation Center, Institute of Convergence Medicine, Ewha Womans University Mokdong Hospital, Seoul, Korea
2 shared publications - Alexei G. Basnakian
University of Arkansas for Medical Sciences
1 shared publication - Eui Man Jeong
Jeju Research Institute of Pharmaceutical Sciences, College of Pharmacy, Jeju National University, Jeju, Korea
1 shared publication - Hwa-Ryeon Kim
Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul, Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 27 April 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (9) , 3886
Dual Targeting of EZH2 and LSD1 Suppresses Hepatocellular Carcinoma via Disruption of Sonic Hedgehog Signaling
Hepatocellular carcinoma (HCC) is a highly aggressive malignancy with poor prognosis and limited therapeutic options. Although epigenetic dysregulation is a hallmark of HCC, rational combinatorial targeting strategies remain incompletely defined. Here, we identify cooperative oncogenic functions of the chromatin modifiers enhancer of zeste homolog 2 (EZH2) and lysine-specific demethylase 1 (LSD1) in HCC. Analysis of the TCGA-LIHC cohort revealed that co-elevated EZH2 and LSD1 expressions are significantly associated with reduced overall survival. Gene set enrichment analysis demonstrated enrichment of Sonic Hedgehog (SHH) signaling and stress-responsive transcriptional programs in tumors with high EZH2/LSD1 expression. Functionally, dual pharmacological inhibition of EZH2 (GSK126) and LSD1 (SP2509) suppressed HCC cell proliferation, induced G1-phase arrest, and enhanced apoptosis, as evidenced by increased caspase-3/7 activity and decreased pro-caspase levels. Dual inhibition also impaired migration, invasion, tumor sphere formation, and stemness-associated gene expression. Mechanistically, co-targeting disrupted SHH signaling through the suppression of GLI1 expression. Chromatin immunoprecipitation revealed reduced EZH2, LSD1, and STAT3 occupancy at the GLI1 promoter following dual inhibition, leading to the repression of GLI1 and its downstream targets. Collectively, these findings demonstrate that EZH2 and LSD1 cooperatively sustain GLI1-dependent SHH signaling in HCC, and that dual epigenetic inhibition represents a mechanistically defined therapeutic strategy.
- 27 April 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (9) , 3886
Open AccessDual Targeting of EZH2 and LSD1 Suppresses Hepatocellular Carcinoma via Disruption of Sonic Hedgehog Signaling
Hepatocellular carcinoma (HCC) is a highly aggressive malignancy with poor prognosis and limited therapeutic options. Although epigenetic dysregulation is a hallmark of HCC, rational combinatorial targeting strategies remain incompletely defined. Here, we identify cooperative oncogenic functions of the chromatin modifiers enhancer of zeste homolog 2 (EZH2) and lysine-specific demethylase 1 (LSD1) in HCC. Analysis of the TCGA-LIHC cohort revealed that co-elevated EZH2 and LSD1 expressions are significantly associated with reduced overall survival. Gene set enrichment analysis demonstrated enrichment of Sonic Hedgehog (SHH) signaling and stress-responsive transcriptional programs in tumors with high EZH2/LSD1 expression. Functionally, dual pharmacological inhibition of EZH2 (GSK126) and LSD1 (SP2509) suppressed HCC cell proliferation, induced G1-phase arrest, and enhanced apoptosis, as evidenced by increased caspase-3/7 activity and decreased pro-caspase levels. Dual inhibition also impaired migration, invasion, tumor sphere formation, and stemness-associated gene expression. Mechanistically, co-targeting disrupted SHH signaling through the suppression of GLI1 expression. Chromatin immunoprecipitation revealed reduced EZH2, LSD1, and STAT3 occupancy at the GLI1 promoter following dual inhibition, leading to the repression of GLI1 and its downstream targets. Collectively, these findings demonstrate that EZH2 and LSD1 cooperatively sustain GLI1-dependent SHH signaling in HCC, and that dual epigenetic inhibition represents a mechanistically defined therapeutic strategy.
- Open Access
- 18 April 2024
- Published by Korean Society for Stem Cell Research in International Journal of Stem Cells
- Vol. 18 (1) , 72-86
Assessment of the Therapeutic Effectiveness of Glutathione-Enhanced Mesenchymal Stem Cells in Rat Models of Chronic Bladder Ischemia-Induced Overactive Bladder and Detrusor Underactivity
Jung Hyun Shin, Hwan Yeul Yu, Hyungu Kwon, Hong Duck Yun, Chae-Min Ryu, Dong-Myung Shin, Myung-Soo Choo. IJSC -0001;0:. https://doi.org/10.15283/ijsc23147
- 18 April 2024
- Published by Korean Society for Stem Cell Research in International Journal of Stem Cells
- Vol. 18 (1) , 72-86
Open AccessAssessment of the Therapeutic Effectiveness of Glutathione-Enhanced Mesenchymal Stem Cells in Rat Models of Chronic Bladder Ischemia-Induced Overactive Bladder and Detrusor Underactivity
Jung Hyun Shin, Hwan Yeul Yu, Hyungu Kwon, Hong Duck Yun, Chae-Min Ryu, Dong-Myung Shin, Myung-Soo Choo. IJSC -0001;0:. https://doi.org/10.15283/ijsc23147
- Open Access
- 17 April 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (16) , eaba1334
Glutathione dynamics determine the therapeutic efficacy of mesenchymal stem cells for graft-versus-host disease via CREB1-NRF2 pathway
Real-time monitoring of GSH dynamics demonstrates the functional roles of CREB1-NRF2 pathway in MSC therapeutic potency.
- 17 April 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (16) , eaba1334
Open AccessGlutathione dynamics determine the therapeutic efficacy of mesenchymal stem cells for graft-versus-host disease via CREB1-NRF2 pathway
Real-time monitoring of GSH dynamics demonstrates the functional roles of CREB1-NRF2 pathway in MSC therapeutic potency.